Pediatric Viral Pneumonia
Conditions
Interventions
Control Group:Symptomatic Treatment
Experimental Group:Symptomatic Treatment and interferon nebulization.
Sponsors
Fujian Children's Hospital,Jin'an District, Fuzhou City,Fujian Province, China
Eligibility
Sex/Gender
All
Age
No minimum to 14 Years
Inclusion criteria
Inclusion criteria: 1. Children aged 2 months to 14 years, inclusive, of either sex; 2. Meeting the diagnostic criteria for pediatric community-acquired pneumonia as defined by the "Management Guidelines for Pediatric Community-Acquired Pneumonia (2024 Revision)".
Exclusion criteria
Exclusion criteria: Those with any of the following conditions should be excluded and excluded from inclusion: 1. Known to be allergic to interferon products; 2. Those with a history of anaphylaxis [A history of anaphylaxis was defined as anaphylaxis of grade 2 or above, in which any of the following clinical manifestations occurred: Airway obstruction (stridor, dyspnea), tachycardia, hypotension, arrhythmia, gastrointestinal symptoms (nausea, vomiting), incontinence, laryngeal edema, bronchospasm, cyanosis, shock, respiratory and cardiac arrest]; 3. Underweight, obesity or growth retardation, height and weight not between -1SD and 1SD for the same age and sex; 4. Asthma history, serious cardiovascular, liver, kidney, hemophilia, autoimmune diseases, respiratory tract dysplasia history, epilepsy or other central nervous system dysfunction and lesions, and pneumonia in the past 3 months; 5. Abnormal laboratory tests during screening: (1) liver function tests: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times of the upper limit of normal value, or total bilirubin > 1.5 times of the upper limit of normal value; (2) Blood routine: white blood cell count 10mg/L, or procalcitonin (PCT) > 0.5µg/L, or the investigator's comprehensive judgment of suspected bacterial infection; 6, screening under the condition of nasal cannula oxygen (oxygen flow <2L/min), percutaneous oxygen saturation (SatO2) < 92% or without oxygen, SatO2< 88%; 7. Extreme restlessness, lethargy, coma, disturbance of consciousness, need to be admitted to ICU, and may need ventilator assisted breathing; 8. Participated in other drug clinical trials 3 months before randomization; 9. Outpatient treatment; 10. Those who were considered unsuitable to participate in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of fever;Duration of cough;Duration of wheezing;Length of hospital stay; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization Costs;Recurrence Rate;Duration of Oxygen Therapy; | — |
Countries
Chian
Contacts
Public ContactTang Qiuyu
Fujian Children's Hospital
Outcome results
None listed